In our study, BUDE was found to improve hepatic injury such as hepatic lipid deposition and fat vacuolization, decrease the expression of inflammatory factor IL-6, as well as increase the mRNA levels of hepatic insulin IRS1, IRS2, and GLUT2, in order to improve the metabolic insulin resistance in metabolically hypertensive rats, and to increase the accumulation of hepatic glycogen content followed by a significant decrease in the TC, LDL-c, and FBG levels of the model rats in order to improve glucose-lipid metabolism disorders. The gene discussed is SLC2A2; the disease is Disorder of lipid metabolism.